

Development of novel therapeutics for ovarian cancer - identification of translesion synthesis (TLS) inhibitors that target Rev1

D5 Therapeutics



ONCOLOGY	Lead
Product Type	Small molecule
Indication	Ovarian cancer, Breast cancer
Target	Rev1
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Inhibition of translesion synthesis (TLS) pathway through blocking of Rev1 and Rev7 protein-protein interaction • Utilization of Rev1 synthetic lethal relationships on BRCA1/2 mutated cancers
Competitiveness	<ul style="list-style-type: none"> • First-in-class therapeutic target • Novel mechanism distinguished from other DNA damage repair targets
Development Stage	Lead
Route of Administration	Oral (PO)